CS MEDICA Receives "Intention To Grant" for European Patent Application Concerning CANNASEN® Psoriasis Gel, Reinforcing Leadership in CBD-infused Dermatological Innovations

Innovative Approach to Compliant Psoriasis Treatment Aims for Patent Protection

CS MEDICA is proud to announce the receipt of an "Intention To Grant" for its patent application from the European Patent Organization (EPO), which has 39 member states[1]. This achievement enhances the protection of its innovative product, CANNASEN® Psoriasis Gel, which contains CBD. This patent discloses a novel treatment approach for psoriasis symptoms such as pain, itch, redness, scaling, and inflammation, along with the specific composition of the psoriasis gel.

Psoriasis, an immune-mediated disorder, affects over 125 million people globally, manifesting in painful symptoms such as itchiness, redness, scaling, and inflammation due to excessive skin cell production triggered by an overactive immune system. Of these, approximately 80% experience mild to moderate symptoms, while 20% suffer from severe forms of the disease. Notably, 50% of all psoriasis patients are actively seeking alternative treatments[2] to avoid the side effects commonly associated with traditional therapies.

Cannabidiol (CBD) is widely acknowledged by scientists and patients for its therapeutic benefits, which include analgesic, anti-inflammatory, immunosuppressive, antiproliferative, and antioxidant properties. Additionally, CBD is known to reduce itching and act as a homeostatic regulator.

CANNASEN® Psoriasis Gel represents a dermatological care breakthrough, harnessing CBD's therapeutic potential. As one of the first compliant substance-based treatments with CBD for psoriasis to achieve patent protection, this marks a significant milestone in dermatological care. The patent approval follows a PCT international application, confirming the company's innovative approach and the effectiveness of its product.

"We are delighted by the 'Intention To Grant' status for our European patent application," stated Lone Henriksen, CEO of CS MEDICA. "This validation underscores our commitment to pioneering innovations that meet stringent regulatory standards, including MDR, MHRA, FDA, and TGA, ensuring our product's compliance and efficacy."

Following the “mention of grant” of the patent application by the EPO, CS MEDICA will initiate the process for national validations for relevant European countries.

Securing patent protection is crucial for a MedTech company like CS MEDICA, as it not only safeguards its intellectual property but also significantly enhances the valuation of the product portfolio. While generating sales in existing markets is vital, obtaining patent protection for innovations like CANNASEN® Psoriasis Gel ensures long-term competitive advantage and opens up additional revenue streams through potential licensing and partnerships. This strategic move underscores the commitment to delivering value to shareholders by protecting and capitalizing on groundbreaking technologies.

"We believe that securing patent protection not only validates our novel approach but also sets a precedent for CBD-infused therapies in dermatology," added Lone Henriksen.

Looking ahead, CS MEDICA expects to obtain patent protection for CANNASEN® Psoriasis Gel across key global markets, including the USA, Canada, India, China, and Australia.

CS MEDICA remains committed to transforming the treatment landscape for people with psoriasis, offering hope for improved quality of life through innovative, safe, and clinically validated solutions.